Tim Freeman - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tim Freeman


Tim Freeman Pharmtech contributing editor and EAB member

Tim Freeman
Managing Director, Freeman Technology

tim.freeman@freemantech.co.uk

www.freemantech.co.uk

Tim Freeman is Managing Director of powder characterization company Freeman Technology for whom he has worked since the mid 1990s. He was instrumental in the original design and continuing development of the FT4 Powder Rheometer and in the past decade has co-led the team that has grown Freeman Technology from a start-up business to the global organization of today. Through his work with various professional bodies and involvement in industry initiatives Tim is an established contributor to wider developments in powder processing.

Tim has a degree in Mechatronics from the University of Sussex in the UK. He has extensive experience in application and method development for the FT4 Powder Rheometer and works closely with customers worldwide across the powder processing industries. Tim is a mentor on a number of project groups for the Engineering Research Center for Structured Organic Particulate Systems in the US. He is a frequent contributor to industry conferences, instructs on training courses for powder processing and writes regularly for a variety of publications.

In the pharmaceutical field Tim is a past Chair of the American Association of Pharmaceutical Scientists (AAPS) Process Analytical Technology Focus Group and is a member of the Editorial Advisory Boards of Life Science Leader magazine (Jameson Publishing Inc. http://www.lifescienceleader.com) and Pharmaceutical Technology (Advanstar Communications Inc. www.pharmtech.com)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here